Malta - English - Medicines Authority

colonis pharma limited quantum house, hobson industrial estate, burnopfield, country, durham ne16 6ea, united kingdom - glycopyrronium bromide - oral solution - glycopyrronium bromide 1 mg/5ml - drugs for functional gastrointestinal disorders

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - glycopyrronium bromide 0.2 mg/ml - solution for injection - 0.2 mg/ml - active: glycopyrronium bromide 0.2 mg/ml excipient: hydrochloric acid sodium chloride water for injection - glycopyrrolate is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions: to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anaesthesia and intubation when indicated. glycopyrronium bromide 200 micrograms per ml solution for injection may be used intraoperatively to counteract drug-induced or vagal traction reflexes with the associated arrhythmias. glycopyrrolate protects against the peripheral muscarinic effects (e.g. bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarising muscle relaxants. for use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.

Ireland - English - HPRA (Health Products Regulatory Authority)

mercurypharm ltd - glycopyrronium bromide - solution for injection - 200 microgram(s)/millilitre - synthetic anticholinergics, quaternary ammonium compounds; glycopyrronium bromide

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

colonis pharma ltd - glycopyrronium bromide - oral solution - 200microgram/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - glycopyrronium bromide 0.5 mg/ml; neostigmine metilsulfate 2.5 mg/ml - solution for injection - active: glycopyrronium bromide 0.5 mg/ml neostigmine metilsulfate 2.5 mg/ml excipient: citric acid citric acid monohydrate dibasic sodium phosphate dodecahydrate sodium hydroxide water for injection - reversal of residual non-depolarising (competitive) neuromuscular block.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - glycopyrronium bromide - solution for injection - 200microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - glycopyrronium bromide - solution for injection - 200microgram/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

mercurypharm ltd - glycopyrronium bromide; neostigmine metilsulfate - solution for injection - 0.5mg /2.5 milligram(s)/millilitre - anticholinesterases; neostigmine, combinations

United Kingdom - English - myHealthbox

dawa limited - glycopyrronium bromide - tablets - 1mg - anticholinergic - for use in adults as add-on therapy in the treatment of peptic ulcer

United Kingdom - English - myHealthbox

dawa limited - glycopyrronium bromide - tablets - 2mg - anticholinergic, - for use in adults as add-on therapy in the treatment of peptic ulcer